GLP-1 hair loss: study finds shedding and scalp changes

People taking GLP-1 medicines reported more hair shedding and scalp symptoms than nonusers in early research presented at a European dermatology conference. For anyone noticing thinning during treatment, the findings raise an important clinical question: is this temporary shedding associated with weight loss, a scalp condition, or a combination of factors?

The research also examined nail changes, but a striking initial association with nail detachment weakened substantially when researchers considered when symptoms began. That distinction matters: a problem recorded during treatment may have existed beforehand, and does not automatically represent a medicine’s side effect.

What happened

According to Healthline and nypost.com, two linked studies examined questionnaire responses from 575 GLP-1 users and 1,329 people with type 2 diabetes, obesity or both who had never taken these medicines. Participants came from France, the United States, Brazil and Mexico. Users had been receiving treatment for an average of 18.5 months.

The findings were presented at the European Academy of Dermatology and Venereology Congress in Vienna in October 2026. Healthline reported that the researchers had submitted the findings to dermatology journals for peer review, the process in which other specialists assess the work before publication.

What the hair findings show

Unusual hair loss was reported by 50% of medicine users, compared with 34% of nonusers. Reduced volume or density — having less hair overall — was reported by 42% and 19%, respectively. These are proportions within the surveyed groups, not a prediction of an individual patient’s likelihood of developing symptoms after starting treatment.

Scalp redness was around three times as common among users. Most users reporting hair loss also described itching, redness or scaling. The researchers suggested that inflammation, the body’s response to irritation or injury, might contribute in some cases. The questionnaire findings do not establish whether it caused the shedding.

Why the nail results need care

Nail detachment, where a nail lifts away from the skin beneath it, was reported by 39% of users and 9% of nonusers. Discolouration affected 46% and 17%. However, about half of the users already had nail problems before treatment, and the detachment association nearly disappeared when only newly developing problems were counted.

Other analyses found that differences persisted among people who had lost weight. Adjusting for reported skin conditions and nutritional deficiencies also weakened some associations, although detachment and discolouration remained roughly two to three times as common. These analyses address different questions: allowing for other conditions is not the same as establishing that symptoms began after exposure.

The background

GLP-1 medicines act on pathways involved in appetite and blood sugar regulation. Semaglutide is sold under names including Ozempic and Wegovy, while tirzepatide, sold as Mounjaro in the UK, acts on both GLP-1 and another hormone pathway called GIP. Products have different licensed uses and should not be treated as interchangeable.

A recognised explanation for shedding after substantial weight loss is telogen effluvium. This happens when more hairs than usual move from active growth into a resting phase, before eventually falling out. It typically causes shedding across the scalp rather than a single smooth bald patch.

The delay in the hair cycle can make the trigger difficult to recognise. Shedding often becomes noticeable around two to three months after a physical stressor, such as illness, surgery or a marked dietary change. Our guide to hair loss after surgery explains how this delayed response can occur after a different physical strain.

Reduced appetite can also make it harder to eat enough protein and obtain essential nutrients. Iron deficiency is one possible contributor to shedding, but it should not be assumed from hair loss alone. A clinician can assess diet, symptoms and whether blood tests would be useful.

Not every change during weight-loss treatment is telogen effluvium. Gradual widening of the parting or thinning at the crown can indicate pattern hair loss, which may become more noticeable alongside increased shedding. Our explanation of female pattern baldness and its treatment options describes this different pattern.

Nails have their own range of possible causes for change, including injury, fungal infection, psoriasis and thyroid disease. Psoriasis is an inflammatory condition that can affect skin and nails. Hair and nail symptoms occurring together therefore warrant a broader assessment rather than an automatic conclusion that a medicine is responsible.